Atika Capital Management’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Atika Capital Management’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-22,000	Closed	-$2.24M	–	107
2023 Q2	$2.24M	Buy	+22,000	New	+$2.08M	0.22%	78
2021 Q3	–	Sell	-48,000	Closed	-$6.79M	–	137
2021 Q2	$6.79M	Buy	+48,000	New	+$5.42M	0.54%	68
2020 Q3	–	Sell	-68,500	Closed	-$10.7M	–	129
2020 Q2	$10.7M	Sell	68,500 -13,500	-16%	-$2.05M	1.38%	22
2020 Q1	$11.8M	Buy	82,000 +19,500	+31%	+$3.76M	2.27%	11
2019 Q4	$12.8M	Buy	+62,500	New	+$11.4M	2.47%	7

Other funds holding RETA

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Atika Capital Management's RETA Position: Q3 2023 in Review

Atika Capital Management sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q3 2023, closing a stake of 22,000 shares — an estimated $2.24M sold.

Atika Capital Management first reported a position in RETA in Q4 2019 and held it in 5 quarters. The position peaked at $12.8M in Q4 2019. 2 funds tracked by Wall St. Rank hold RETA as of Q3 2023.

Atika Capital Management reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q3 2023 after selling out during the quarter.
Atika Capital Management sold 22,000 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q3 2023, an estimated $2.24M.
Atika Capital Management first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2019 and held it in 5 quarters.
Atika Capital Management's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $12.8M in Q4 2019.
2 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q3 2023.

Based on Atika Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.